Abstract
The aim of this study was to determine if Rituximab coated Biodegradable Nanoparticles (BNPs) loaded with Chlorambucil and Hydroxychloroquine could induce apoptosis of B-Chronic Lymphocytic Leukemia (B-CLL), MEC-1 and BJAB cells in vitro and evaluate their toxic and therapeutic effects on a Human/Mouse Model of Burkitt Lymphoma at an exploratory, proof of concept scale. We found that Rituximab-Chlorambucil-Hydroxychloroquine BNPs induce a decrease in cell viability of malignant B cells in a dose-dependent manner. The mediated cytotoxicity resulted from apoptosis, and was confirmed by monitoring the B-CLL cells after Annexin V/propidium iodide staining. Additional data revealed that these BNPs were non toxic for healthy animals, and had prolonged survival in this mice model of human lymphoma.
Keywords: B cells, CLL, lymphoma, nanoparticles, chlorambucil, hydroxychloroquine, rituximab.
Current Clinical Pharmacology
Title:Exploratory Study on the Effects of Biodegradable Nanoparticles with Drugs on Malignant B Cells and on a Human/Mouse Model of Burkitt Lymphoma
Volume: 5 Issue: 4
Author(s): Gustavo H. Marin, Eduardo Mansilla, Nelly Mezzaroba, Sonia Zorzet, Luis Nunez, Gustavo Larsen, Jose M. Tau, Alberto Maceira, Ruben Spretz, Carol Mertz, Sabrina Ingrao, Claudio Tripodo, Francesco Tedesco and Paolo Macor
Affiliation:
Keywords: B cells, CLL, lymphoma, nanoparticles, chlorambucil, hydroxychloroquine, rituximab.
Abstract: The aim of this study was to determine if Rituximab coated Biodegradable Nanoparticles (BNPs) loaded with Chlorambucil and Hydroxychloroquine could induce apoptosis of B-Chronic Lymphocytic Leukemia (B-CLL), MEC-1 and BJAB cells in vitro and evaluate their toxic and therapeutic effects on a Human/Mouse Model of Burkitt Lymphoma at an exploratory, proof of concept scale. We found that Rituximab-Chlorambucil-Hydroxychloroquine BNPs induce a decrease in cell viability of malignant B cells in a dose-dependent manner. The mediated cytotoxicity resulted from apoptosis, and was confirmed by monitoring the B-CLL cells after Annexin V/propidium iodide staining. Additional data revealed that these BNPs were non toxic for healthy animals, and had prolonged survival in this mice model of human lymphoma.
Export Options
About this article
Cite this article as:
H. Marin Gustavo, Mansilla Eduardo, Mezzaroba Nelly, Zorzet Sonia, Nunez Luis, Larsen Gustavo, M. Tau Jose, Maceira Alberto, Spretz Ruben, Mertz Carol, Ingrao Sabrina, Tripodo Claudio, Tedesco Francesco and Macor Paolo, Exploratory Study on the Effects of Biodegradable Nanoparticles with Drugs on Malignant B Cells and on a Human/Mouse Model of Burkitt Lymphoma, Current Clinical Pharmacology 2010; 5 (4) . https://dx.doi.org/10.2174/157488410793352058
DOI https://dx.doi.org/10.2174/157488410793352058 |
Print ISSN 1574-8847 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3938 |
Related Articles
-
Hematopoietic Stem Cells Therapies
Current Stem Cell Research & Therapy Recent Advances in the Development of Immunoadhesins for Immune Therapy and as Anti-Infective Agents
Recent Patents on Anti-Infective Drug Discovery Identification of Small Molecule Binding Sites within Proteins Using Phage Display Technology
Combinatorial Chemistry & High Throughput Screening Cellular and Molecular Surrogate Markers to Monitor Targeted and Non- Targeted Antiangiogenic Drug Activity and Determine Optimal Biologic Dose
Current Cancer Drug Targets A Century of Thioxanthones: Through Synthesis and Biological Applications
Current Medicinal Chemistry Main Nutritional and Environmental Risk Factors in Children with Leukemia from a Public Hospital of the State of Guanajuato, Mexico
Current Cancer Therapy Reviews The Endocannabinoid System in Amyotrophic Lateral Sclerosis
Current Pharmaceutical Design Plasticity and Therapeutic Potential of Mesenchymal Stem Cells in the Nervous System
Current Pharmaceutical Design Relevance of Cytochrome P450 Polymorphisms in the Treatment of Helicobacter pylori Infection and Gastroesophageal Reflux Disease
Current Pharmacogenomics Editorial (Thematic Issue: Advances in Drug Discovery for the Treatment of Cancer: Many Approaches, One Goal)
Current Topics in Medicinal Chemistry Optimization of Drug Safety Profile in Inflammatory Bowel Disease Through a Personalized Approach
Current Drug Targets Hypoxia: Targeting the Tumour
Anti-Cancer Agents in Medicinal Chemistry Neurokinin Receptors as Potential Targets in Breast Cancer Treatment
Current Drug Discovery Technologies Radioprotective Effects of Plants from the Lamiaceae Family
Anti-Cancer Agents in Medicinal Chemistry Invasive Aspergillosis: New Insights into Disease, Diagnostic and Treatment
Current Pharmaceutical Design Review of Antibiotic and Non-Antibiotic Properties of Beta-lactam Molecules
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Characteristics, Functions and Inhibitors of Three Aminopeptidases Belonging to the M1 Family
Current Protein & Peptide Science Antibody-Targeted Immunoliposomes for Cancer Treatment
Mini-Reviews in Medicinal Chemistry Membrane Transporters as Determinants of the Pharmacology of Platinum Anticancer Drugs
Current Cancer Drug Targets Antioxidant Therapeutic Approaches Toward Amelioration of the Pulmonary Pathophysiological Damaging Effects of Ionizing Irradiation
Current Respiratory Medicine Reviews